EUVIMEDEUVIMED entdecken
Open Access

ATR inhibition using gartisertib enhances cell death and synergises with temozolomide and radiation in patient-derived glioblastoma cell lines

Mathew Lozinski, Nikola A Bowden, Moira C Graves, Michael Fay, Bryan W Day, Brett W Stringer, Paul A Tooney

Oncotarget · 16.01.2024 · 15 (1) · 1-18

DOI: 10.18632/oncotarget.28551 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Oncotarget, online erschienen am 16.01.2024. Verfasst von Mathew Lozinski und 6 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine and Public Health, College of Health, Medicine and Wellbeing, University of Newcastle, NSW, Australia. Hauptthemen laut MEDLINE: Glioblastoma, Brain Neoplasms. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GlioblastomaBrain NeoplasmsHumansTemozolomideDacarbazineAntineoplastic Agents, AlkylatingTumor Suppressor ProteinsCell DeathCell LineDNACell Line, TumorDNA Modification MethylasesDNA Repair EnzymesAtaxia Telangiectasia Mutated Proteins

Stichwörter der Autor:innen

DNA damage responseataxia-telangiectasia and rad3-related proteinglioblastomaradiation therapytemozolomide

Substanzen

TemozolomideDacarbazineAntineoplastic Agents, AlkylatingTumor Suppressor ProteinsDNADNA Modification MethylasesDNA Repair EnzymesATR protein, humanAtaxia Telangiectasia Mutated Proteins

Autor:innen und Institutionen

  • School of Medicine and Public Health, College of Health, Medicine and Wellbeing, University of Newcastle, NSW, Australia.
  • Drug Repurposing and Medicines Research Program, Hunter Medical Research Institute, New Lambton, NSW, Australia.
  • Mark Hughes Foundation Centre for Brain Cancer Research, University of Newcastle, NSW, Australia.
  • GenesisCare, Newcastle, NSW, Australia.
  • QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia.
  • Griffith Institute for Drug Discovery, Griffith University, Brisbane, QLD, Australia.

Zitieren

APA

Lozinski, M., Bowden, N. A., Graves, M. C., Fay, M., Day, B. W., Stringer, B. W., & Tooney, P. A. (2024). ATR inhibition using gartisertib enhances cell death and synergises with temozolomide and radiation in patient-derived glioblastoma cell lines. Oncotarget, 15(1), 1-18. https://doi.org/10.18632/oncotarget.28551

Vancouver

Lozinski M, Bowden NA, Graves MC, Fay M, Day BW, Stringer BW, et al. ATR inhibition using gartisertib enhances cell death and synergises with temozolomide and radiation in patient-derived glioblastoma cell lines. Oncotarget. 2024;15(1):1-18. doi:10.18632/oncotarget.28551

BibTeX
@article{Lozinski2024,
  author = {Lozinski, Mathew and Bowden, Nikola A and Graves, Moira C and Fay, Michael and Day, Bryan W and Stringer, Brett W and Tooney, Paul A},
  title = {ATR inhibition using gartisertib enhances cell death and synergises with temozolomide and radiation in patient-derived glioblastoma cell lines},
  journal = {Oncotarget},
  year = {2024},
  volume = {15},
  number = {1},
  pages = {1--18},
  doi = {10.18632/oncotarget.28551}
}
Kostenlos starten →